Tech Company Financing Transactions

SutroVax Funding Round

SutroVax closed a $85 million Series C funding round on 6/8/2018. Investors included TPG Growth, Abingworth and CTI Life Sciences Fund.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

353 Hatch Dr.
Foster City, CA 94404
USA

Phone

(650) 837-0111

Website

www.sutrovax.com

Email Address

[email protected]

Overview

SutroVax is an independent vaccine platform and development company that was spun-out of Sutro Biopharma. The company will leverage Sutro's Xpress CF and Xpress CF+ platforms for cell-free protein synthesis and site-specific conjugation to develop novel vaccines for an array of disease targets.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Grant Pickering

        

Chief Medical Officer

Alan Kimura

        

Chief Operating Officer

James Wassil

        

VP - General Counsel

Jane Mitchell

        

VP - Manufacturing

Paul Sauer

        

VP - R & D

Jeff Fairman

        

Browse more venture capital transactions:

Prev: 6/8/2018: EON Foundation venture capital transaction
Next: 6/8/2018: Starship Technologies venture capital transaction

Share this article

Where The Data Comes From

We report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary